Prevalence of Upper Gastrointestinal Bleeding in Antithrombotic Agent Treatment: Wakayama UGB Registry

Prevalence of Upper Gastrointestinal Bleeding in Antithrombotic Agent Treatment: Wakayama UGB Registry - Prevalence of Upper Gastrointestinal Bleeding in Antithrombotic Agent Treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035358

Enrollment

1000

Registered

2019-01-01

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Gastrointestinal Bleeding

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients contined antithrombotic agent treatment for three months. This study was written informed consent was obtained from all patients.

Exclusion criteria

Exclusion criteria: Patients have been already done for upper endoscopy within three months.

Design outcomes

Primary

Measure	Time frame
Upper Gastrointestinal Bleeding	—

Countries

Japan

Contacts

Public Contacttakashi yamano

Wakayama medical university Department of cardiovascular medicine

ymntks@wakayama-med.ac.jp0734772300

Outcome results